VAR - Varian Medical Systems, Inc.
| Previous Close | 110.36 |
| Open | 110.23 |
| Bid | 89.00 x 800 |
| Ask | 113.65 x 800 |
| Day's Range | 110.11 - 111.31 |
| 52 Week Range | 98.34 - 130.29 |
| Volume | 680,929 |
| Avg. Volume | 611,392 |
| Market Cap | 10.181B |
| Beta | 1.08 |
| PE Ratio (TTM) | 72.03 |
| EPS (TTM) | 1.54 |
| Earnings Date | Oct 23, 2018 - Oct 29, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 1998-12-02 |
| 1y Target Est | 121.57 |
- GlobeNewswire•5 days ago
New Research Coverage Highlights Arena Pharmaceuticals, Varian Medical, SS&C Technologies, Globus Medical, Zynga, and Diamondrock Hospitality — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Arena ...
- Zacks•9 days ago
Varian Acquires humediQ, Boosts Motion Management Portfolio
Varian (VAR) incorporates humediQ's coveted IDENTIFY technology in its comprehensive suite of oncology solutions.
Markit•11 days agoSee what the IHS Markit Score report has to say about Varian Medical Systems Inc.
Varian Medical Systems Inc NYSE:VAR
InvestorPlace•12 days ago3 Big Stock Charts for Tuesday: GGP, Alaska Air Group and Varian Medical Systems
Far more tame were stock charts of GGP (NYSE:GGP), Alaska Air Group (NYSE:ALK) and Varian Medical Systems (NYSE:VAR), which are heading into Tuesday’s action as a trader’s top prospects — largely because they didn’t dish out tricky, unfounded volatility. Both are trends that retail space landlord GGP benefit from. • There’s a likely resistance line at $23.85, where VAR bumped into a technical ceiling late last year and early this year.
- Benzinga•13 days ago
Merger Monday Returns With A Vengeance
Monday saw a heavy slate of M&A announcements. Here are some of the most significant involving publicly traded companies: Amcor Limited will purchase Bemis Company, Inc. (NYSE: BMS ) in a $6.8 billion ...
- PR Newswire•13 days ago
Varian Announces Acquisition of humediQ Global GmbH
Acquisition expands Varian's motion-management portfolio and presence in Germany PALO ALTO, Calif. , Aug. 6, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced the acquisition of privately-held humediQ ...
Market Realist•13 days agoWhy ViewRay Stock Fell 9.4% on August 3
On August 3, ViewRay (VRAY) reported revenues of $16.4 million for the second quarter of 2018, which is a YoY (year-over-year) rise of 2,248.6%. The performance was driven by the recognition of revenues related to the sale of three MRIdian Linacs for MRI-guided radiation therapy. It also received new orders worth $34.6 million for its MRIdian systems. At the end of the quarter, it had a backlog of orders worth $200 million, which is a YoY rise of 11.1%.
Markit•17 days agoSee what the IHS Markit Score report has to say about Varian Medical Systems Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Thomson Reuters StreetEvents•18 days ago
Edited Transcript of VAR earnings conference call or presentation 25-Jul-18 9:00pm GMT
Q3 2018 Varian Medical Systems Inc Earnings Call
- Market Realist•19 days ago
What Analysts Recommend for Hologic ahead of Third-Quarter Results
Hologic (HOLX), a leading women’s health technology player, will release its fiscal third-quarter earnings results on July 31 after markets close. The stock fell more than 9% following the results. Many analysts covering Hologic cut their target prices on HOLX stock in the following days. As of July 30, Reuters reported that of the 19 analysts covering Hologic, ~63% have a “buy” or “strong buy” rating on HOLX stock.
Markit•22 days agoSee what the IHS Markit Score report has to say about Varian Medical Systems Inc.
Varian Medical Systems Inc NYSE:VAR
Market Realist•23 days agoVarian Medical Systems’ Fiscal Q3 2018 Performance
Varian Medical Systems (VAR) reported its fiscal Q3 2018 results on July 25. Net sales surged 12% YoY (year-over-year) from $632.8 million to $709.1 million.
Market Realist•23 days agoHow Baxter International Fared in the Second Quarter
Baxter International (BAX) released its Q2 2018 results on July 26. During the quarter, Baxter expanded its medication delivery portfolio with two new infusion pumps. Baxter International’s marketing and administrative expenses increased 8% from $630 million in Q2 2017 to $681 million in Q2 2018, and its research and development expenses increased by 12% from $155 million in Q2 2017 to $174 million in Q2 2018.
- Zacks•24 days ago
Varian Medical (VAR) Beats Q3 Earnings & Revenue Estimates
Varian Medical (VAR) see strong growth in Oncology Systems. Solid guidance boosts investors' optimism.
- PR Newswire•25 days ago
Varian Reports Results for Third Quarter of Fiscal Year 2018
Third Quarter 2018 Summary − Revenues of $709 million grew 12 percent, or 10 percent in constant currency − Oncology gross orders grew 11 percent, or 9 percent in constant currency − GAAP operating earnings ...
- ACCESSWIRE•25 days ago
Varian Medical Systems, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July 25, 2018 / Varian Medical Systems, Inc. (NYSE: VAR) will be discussing their earnings results in their Q3 Earnings Call to be held on July 25, 2018 at 5:00 PM Eastern Time. ...
Market Realist•25 days agoVarian Medical Systems’ Bottom-Line Expectations in Q3 2018
Varian Medical Systems (VAR) is expected to incur SG&A (selling, general, and administrative) expenses of $120.88 million in Q3 2018 compared to $55.1 million in Q3 2017, an increase of more than 100%. The company’s R&D (research and development) expenses are expected to increase 0.94%, from $55 million in Q3 2017 to $55.6 million in Q3 2018. Its total operating expenses are expected to increase 0.97%, from $171.8 million in Q3 2017 to $173.48 million in Q3 2018.
Market Realist•25 days agoWhat to Expect from Varian Medical Systems’ Q3 2018 Earnings
Varian Medical Systems (VAR) is expected to report its fiscal Q3 2018 earnings on July 25. In this series, we’ll be taking a look at its expected top line and its operational and bottom-line performances for the third fiscal quarter. Varian is engaged in the design, manufacture, and commercialization of hardware and software products for the treatment of cancer with radiotherapy, stereotactic radiosurgery, brachytherapy, and stereotactic body radiotherapy.
- Zacks•26 days ago
Medical Product Earnings Lineup for Jul 25: TMO, BSX & More
The Medical product market further gains momentum on the back of a recent two-year suspension of the controversial 2.3% Medical Device tax.
- PR Newswire•26 days ago
Varian Showcases Advanced Cancer Care Solutions at AAPM 2018
PALO ALTO, Calif. , July 24, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced it will be showcasing its advanced cancer care solutions including a new version of Eclipse ™ treatment planning software ...
- Reuters•last month
BRIEF-Sirtex Medical Updates On Payment Of A$15.8 Mln Break Fee To Varian
July 13 (Reuters) - Sirtex Medical Ltd: * PAYMENT OF A$15.8 MILLION BREAK FEE TO VARIAN * CONFIRMS HAS RECEIVED CASH REIMBURSEMENT FROM CDH-CGP EQUIVALENT TO AMOUNT PAID TO VARIAN Source text for Eikon: ...
- Zacks•last month
Varian Medical (VAR) Q3 Earnings: Surprise in Store?
Solid prospects in the Oncology segment is likely to boost Varian Medical's (VAR) top-line performance in the third quarter of fiscal 2018.
- The Wall Street Journal•last month
[$$] With Tariff Deadline at Hand, Businesses Brace for the Fallout
Businesses are bracing for disruptions in sales and supply chains as the U.S. and China hurtle toward levying tit-for-tat tariffs on billions of dollars in automotive products, farm crops and other goods. The U.S. imposed tariffs on $34 billion worth of imported Chinese machinery, auto parts and medical devices at 12:01 a.m. Eastern time Friday. China said it is prepared to respond immediately with equivalent tariffs on U.S. products including soybeans and sport-utility vehicles.
- The Wall Street Journal•2 months ago
[$$] Sirtex Medical Gets Go-Ahead From Australian Regulator for Sale
An Australian regulator has approved the sale of Sirtex Medical to CDH Investments and China Grand Pharmaceutical and Healthcare Holdings.
- Zacks•2 months ago
Here's Why You Should Hold Varian Medical (VAR) Stock Now
Here we analyze the major factors that have been plaguing Varian Medical (VAR) and discuss the prospects that ensure near-term recovery.
